Background: It is unknown how subsequent breast cancer outcomes vary by biologic subtype and race/ethnicity in a diverse cohort of breast cancer survivors.
IntroductIon
Sparse data exist about breast cancer outcomes in minority women. Despite improvements in early detection and treatment strategies based on consideration of biologic subtype classifications of breast tumors, differences in breast cancer mortality persist when comparing African American and White patients, 1 and even fewer studies include Asian women. Current breast cancer therapy is based on breast cancer subtyping via tumor receptors for estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2). [2] [3] [4] [5] These subtypes include luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), triple negative (ER-/ PR-/HER2-) and HER2-enriched (HER2+/ER-/PR-). [4] [5] [6] Racial disparities in survival may be attributed to both biologic (eg, subtype, tumor characteristics, molecular abnormalities that accelerate progression) and non-biologic factors (eg, socioeconomic status, insurance coverage). [7] [8] [9] Although recurrence risk by breast cancer subtypes has been examined, surprisingly few studies have included adequate numbers of minority women, particularly from Asian subgroups, precluding evaluation of potential racial/ethnic disparities by biologic subtypes. Previous studies that examined racial/ethnic disparities in breast cancer prognosis were limited by small numbers of breast cancer events, 10 or lacked comprehensive information on breast cancer therapy. 1, 11 
Biologic Subtypes and Data Elements
Data elements were extracted from medical records review, cancer registry, electronic health records, and state and national mortality databases. Biologic Information on sociodemographics, tumor characteristics, primary cancer treatments (surgery type, radiotherapy, chemotherapy), and co-morbidity, were collected from electronic health records and cancer registry. Use of adjuvant endocrine therapy, tamoxifen and aromatase inhibitors was extracted from electronic pharmacy records. Date and cause of death were ascertained using KPSC membership records, and State of California and national Social Security Administration's mortality databases. Socioeconomic status (SES) information was based on California's 2000 census. Women were classified according to the median family household income of their census block at the time of diagnosis.
Study Outcome
Local or regional recurrence, development of metastasis, new contralateral breast cancer, and breast cancer-specific death (deaths attributed to the breast cancer) were combined into one composite outcome, subsequent breast cancer, based on whichever event occurred first. New second primary tumors (ipsilateral and contralateral breast) cancers were identified from the cancer registry, and included noninvasive or invasive cancers, and must have occurred at least six months after initial breast cancer surgery. Recurrences included lesions occurring in the ipsilateral breast at least six months after initial breast cancer surgery, with or without spread to regional areas (eg, nearby axillary lymph nodes), or distant metastasis. Recurrences were identified through manual review of all available pathology reports (two-thirds of the cohort), and by electronic health record review when pathology reports were unavailable. 12 Our hybrid approach of manually reviewing pathology text supplemented with an automated data algorithm applied to the electronic health record databases was validated (sensitivity 96.9%; specificity 92.4%). 12 We examined these outcomes as a composite because new second pri- 
Methods

Study Population and Setting
Our study was based in a large integrated health care delivery system, Kaiser Permanente Southern California, which serves 4.3 million members (approximately 25% of the southern California population) with equal access to health care. We identified 6,154 women diagnosed with Breast Cancer Outcomes by Race/Ethnicity -Haque et al mary cancer in the contralateral breast (1.5% of outcomes) were rare.
Statistical Analysis
We initially examined the overall rates of subsequent breast cancer events stratified by race/ethnicity and biologic subtype. Demographic characteristics, tumor characteristics and treatment for the primary breast cancer were categorized and compared using chi-square or Fisher's exact tests, and a P<.05 (twosided) was considered statistically significant. Follow-up commenced on the date of the primary breast cancer diagnosis and ended on the date of a subsequent breast cancer, date of death, termination of health plan membership, or study's end (January 1, 2010), whichever occurred first. Hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazards models with time-dependent primary treatment variables (adjuvant tamoxifen and/ or aromatase inhibitors, radiation, and chemotherapy), and adjustment for covariates (age and stage at diagnosis; Charlson comorbidity index; geocoded income; histology; grade; lymph node status; surgery; number of healthcare visits during follow-up). We also conducted a sensitivity analysis excluding the few who developed a new second primary cancer in the contralateral breast (n=96 or 1.5%). The proportionality assumption was examined through both residual analysis and testing interactions between time and the main variables of subtype and race/ethnicity; we observed no deviations. All analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, North Carolina).
results
The cohort of 6,154 women with incident breast cancer with median age of 59 years (SD=12.9 years) was followed a maximum of 13 years (Table  1) . Asian women, particularly South Asians, were diagnosed with breast cancer at younger ages compared with Whites and were more likely to be in higher socioeconomic status (SES) groups. African American women were more likely to be in the lower SES group. More than 70% of the cohort had no major comorbidity. More African American women (34.9%) had a Charlson comorbidity index >1 than White women (28.7%).
The distribution of tumor characteristics and cancer treatment by race/ ethnicity are displayed in Table 2 . Overall, luminal A breast cancer was the most common (58.7%), followed by triple negative cancer (24.8%), HER-2 enriched (9.3%) and luminal B (7.3%). Fractions of each subtype varied by race/ethnicity (P<.01). Triple-negative breast cancer was more common in African American women (40.3%) than in White women (21.2%). The fraction of luminal B was higher in South Asians (10.7%), Chinese (13.9%), and Other Asians (14.2%) compared with White women (6.7%). Filipina women (14.5%) and Other Asian (13.0%) women had the highest fractions of HER2-enriched disease. Nearly 83% of the cohort was diagnosed with early stage disease (AJCC TNM stages 0-II). Invasive histology was more common in African American, South Asian, and Other Asian women (P<.01). Minority women, particularly African Americans and Other Asians, had higher grade tumors. A higher proportion of minority women, in general, underwent chemotherapy (P<.01). Use of adjuvant tamoxifen or aromatase inhibitors was similar across all groups in women who were ER+ or PR+, except among African American women who were less likely to use this adjuvant therapy.
subsequent breast cancer events
In the cohort of 6,154 women, we identified 1,456 subsequent breast cancer events over 22,830 personyears total (median 3.1 years) ( Table  2) . Of the 1,456 subsequent breast cancer events, 1087 (74.6%) were recurrences, 96 (6.6%) were new contralateral breast tumors, 17 (1.2%) were second primary tumors (ipsilateral breast), and 256 (17.6%) were breast cancer deaths. A large fraction of the cohort survived through the end of study, N=3670 (59.6%). The median time to subsequent breast cancer was 22 months (interquartile range [IQR]: 13-38 months) in women with luminal A tumors; 13 months (IQR: 12-19 months) for luminal B; 16 months (IQR: 12-26 months) for triple negative; and 14 months for HER-2 enriched (IQR: 12-22 months). The median times to subsequent breast cancer events did not vary substantially by race/ethnicity (data not shown). Figure 1 and Table 3 show the absolute subsequent breast cancer rates stratified by race/ethnicity and subtype. Overall, the absolute subsequent breast cancer rate was greatest among those with HER-2 enriched, followed by luminal B, triple-negative, and luminal A, respectively (Figure 1 ). In women with luminal A subtype, crude subsequent breast cancer rates were highest among African American (48/1,000 person-years, PY) and Chinese women (47/1,000 PY), respectively, vs Whites (34/1,000 PY). In women with luminal B tumors, minority groups had higher rates of subsequent breast cancer compared with Whites (147/1,000 PY): 192/1,000 PY for Hispanics, 191/1,000 PY for African Americans, and 172/1,000 PY for Asians. In women with triple negative tumors, the subsequent cancer rates were higher among Filipinas (103/1,000 PY), Japanese (154/1,000 PY) and African American women (89/1,000), than in Whites (68/1,000 PY) or Hispanics (70/1,000 PY). In contrast, in women with HER2-enriched subtype, Hispanics (212/1,000 PY) and Filipinas (236/1,000 PY) had higher subsequent breast cancer rates, while African American (140/1,000 PY) women had a lower rate than Whites (181/1,000 PY).
Although we observed disparities in crude person-year rates within each biologic subtype by race/ethnicity, these differences attenuated when examining the adjusted hazard ratios (HR) for each minority group as compared with Whites (Table 3) We found no increased risks in other subgroups of Asian women, possibly due to the small number of events.
In the sensitivity analysis in which we excluded few women who developed a new second primary in the contralateral breast (N=96 out of 1,456 SBC events or 1.5%), the HRs remained the same (data not shown). Table 4 displays the independent association of tumor characteristics (biologic subtype, stage, grade, lymph nodes), race/ethnicity, primary cancer treatments, and adjuvant therapy with the risk of subsequent breast cancer. In terms of adjusted relative risks, the risk of subsequent breast cancer was 3.65 times greater (adjusted HR=3.65, 95% CI: 3.08-4.32) in women with luminal B tumors as compared with luminal A (reference group) after accounting for sociodemographics, tumor characteristics, cancer treatments, and comorbidity. Women with HER-2 enriched tumors had a risk 2.81 times greater (adjusted HR=2.81, 95% CI: 2.25-3.51) than with luminal A tumors. Women with triple-negative tumors had a risk 1.25 times greater (adjusted HR=1.25, 95% CI: 1.01-1.54) than with luminal A tumors. Consistent with the lack of racial/ethnic disparities within each biologic subtype group implied in Table 3 , the risk of subsequent breast cancer was comparable in each race/ ethnic group after adjusting for biologic subtype, tumor characteristics, and cancer treatments. Of note, factors that were statistically significantly associated with increased risk of subsequent breast cancer included luminal B, HER2-enriched, or triple negative subtype, higher tumor grade, larger tumor size, positive lymph nodes, and non-use of adjuvant treatments (chemotherapy or endocrine treatments) (all P <.025 from the aforementioned multivariable model, Table 4 ).
dIscussIon
In this diverse cohort of insured breast cancer survivors, we found that crude risk of subsequent breast cancer was greater in some racial/ ethnic groups compared with White women. For example, in women with triple negative tumors, Filipina, Japanese and Hispanic women had the highest rates of subsequent breast cancer as compared with Whites. Similarly, in women with luminal B tumors, African American and Hispanic had higher rates of subsequent breast cancer than Whites. However, within each biologic subtype, the racial/ethnic differences in developing subsequent breast cancer disappeared after multivariable adjustment for tumor characteristics, primary and adjuvant cancer treatments, and sociodemographics. Interestingly, we found a statistically significant 42% lower risk of subsequent breast cancer events in African American women with HER2-enriched tumors as compared with White women with HER2-enriched tumors. This reduced risk may reflect differences in reproductive risk factors or lifestyle factors that we could not assess. Our combined results suggest that biologic subtype, tumor characteristics at diagnosis, and cancer treatments play a greater role in predicting breast cancer outcomes, rather than race/ethnicity, at least in this managed care population in which bias due to variable medical coverage was reduced. Although prior reports suggest that women with triple negative breast cancer have worse outcomes, 2, 8 the risk of subsequent breast cancer was even greater in women Our finding of a greater risk of subsequent breast cancer in women with luminal B tumors compared with luminal A tumors is consistent with a previous report of a higher recurrence score (as defined by gene predictor of distant relapse). 5 The lower risk of subsequent breast cancer events in ER-negative tumors (ie, triple negative and HER2-enriched), may reflect that these two biologic subtypes respond better to chemotherapy, as compared with luminal B tumors. 13 Our study has several strengths. The cohort was diverse and of the 6,154 women, 37% were from minority backgrounds, thus enhancing generalizability of our study. Importantly, given that all women were insured, this decreased the bias that stemmed from variable medical coverage often correlated with poor outcomes. Also, due to the comprehensive data from the electronic health records, we examined risks accounting for a broad set of key potential confounders, including number of health care visits during the followup which includes breast cancer surveillance. Further, we examined chemotherapy and endocrine therapy captured from electronic pharmacy dispensing records as time-dependent variables ensuring that women were exposed to the treatment, and the treatment effect estimates were valid. Moreover, we identified the majority of recurrences using medical chart review supplemented by information from the cancer registry or a validated computerized algorithm applied to the electronic health record. 12 However, certain limitations must be considered. We were not able to further adjust for birth place of the patients; birth place may influence subsequent breast cancer risk due to early life environmental exposures and behaviors related to residency. 14 Although the median follow-up of 3.1 years suggests the findings are ever, oral tamoxifen and aromatase inhibitors remain the cornerstone treatment for women with ER+ and/ or PR+ (Luminal A and B) tumors, and we considered those medications in our analysis. Nonetheless, our results may not apply to women treated with newer chemotherapies.
conclusIons
We determined that biologic subtype, worse tumor characteristics, and lack of adjuvant endocrine or chemotherapy are more strongly correlated with the risk of subsequent breast cancer than women's race/ethnicity in a cohort of insured women. Women with luminal B tumors were more than three times likely to develop subsequent breast cancer events vs those with luminal A tumors. Women with HER2-enriched tumors were more than two times likely to develop subsequent breast cancer events, while women with triple negative tumors were 25% more likely, as compared with women with luminal A tumors. Further, within each biologic subtype, the racial/ethnic disparities in the adjusted risk of subsequent breast cancer attenuated in the multivariable models. Our results suggest that recommending appropriate (and reducing health care barriers to) adjuvant endocrine and chemotherapy based on the tumor's biologic characteristics could dramatically reduce any apparent disparities in breast cancer outcomes. This study was supported by National Institutes of Health/National Cancer Institute R01CA093772 (RH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
